Nektar Therapeutics (NKTR) PT Lowered to $4.60 at Stifel, "NKTR-358 Remains Biggest Potential Value Driver"
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $4.60 (from $4.70) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
